Scottish Medicines Consortium nilotinib (Tasigna)

Scottish Medicines Consortium nilotinib (Tasigna)

in the absence of a submission from the holder of the marketing authorisation

nilotinib (Tasigna®) is not recommended for use within NHS Scotland.

Indication under review:

  • paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase
  • paediatric patients with Philadelphia chromosome positive CML in chronic phase with resistance or intolerance to prior therapy including imatinib

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting.  As a result we cannot recommend its use within NHSScotland.

Drug Name: nilotinib (Tasigna)
SMC Drug ID: 1325/18
Manufacturer: Novartis Pharmaceuticals UK Ltd
Indication: Paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase, and Paediatric patients with Philadelphia chromosome positive CML in chronic phase with resistance or intolerance to prior therapy including imatinib
BNF Category:
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 12 March 2018

To read more Press Release articles, click here.